Retension Pharmaceutical key facts
as of Oct 2026- Developer of therapeutic drugs designed for patients with hypertension.
- Retension Pharmaceutical is valued at approximately $50.0M as of Oct 2026 (last reported valuation).
- It has raised $22.4M; the latest was Early Stage VC ($12.3M) in May 2025.
- Notable investors include Dais Partners, Collage Venture Partners, Green Park & Golf Ventures, Transhuman Capital.
- Status: Privately Held (backing).
Retension Pharmaceutical's last reported valuation, May 2025. Nothing priced has surfaced since.
- ·Watch Retension Pharmaceutical: the Monday email on marks, rounds and moves
Retension Pharmaceutical funding rounds
No funding rounds for Retension Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Retension Pharmaceutical
4Retension Pharmaceutical valuation
Retension Pharmaceutical's last reported valuation was $50 million in May 2025. No priced round, secondary trade or fund mark has surfaced since.
Retension Pharmaceutical investors
4 investors are on record for Retension Pharmaceutical, including Dais Partners, Collage Venture Partners, Green Park & Golf Ventures and Transhuman Capital.
About Retension Pharmaceutical
Developer of therapeutic drugs designed for patients with hypertension. The company's drug is a unique second-generation inhibitor that preferentially targets cardiovascular tissues, enabling patients to control blood pressure and improve cardiovascular health.
- Sector
- Healthcare
- HQ
- Falls Church, VA, United States
- Founded
- 2023
- Employees
- 9
- Website
- retensionpharma.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.